Published in J Natl Cancer Inst on December 11, 2007
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA (2008) 2.73
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet (2014) 2.72
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Current status of genome-wide association studies in cancer. Hum Genet (2011) 2.14
Prostate cancer genomics: towards a new understanding. Nat Rev Genet (2008) 2.08
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J Natl Cancer Inst (2010) 2.00
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A (2009) 1.69
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet (2008) 1.57
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate (2008) 1.53
AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory angiogenesis in mice. J Clin Invest (2008) 1.49
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
A novel prostate cancer susceptibility locus at 19q13. Cancer Res (2009) 1.49
Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet (2014) 1.48
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Genome-wide association studies of cancer. J Clin Oncol (2010) 1.45
Do environmental factors modify the genetic risk of prostate cancer? Cancer Epidemiol Biomarkers Prev (2014) 1.42
Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3. PLoS One (2011) 1.41
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis (2011) 1.37
Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.37
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci (2011) 1.32
Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res (2009) 1.29
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Early onset prostate cancer has a significant genetic component. Prostate (2011) 1.26
Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol (2011) 1.23
Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res (2008) 1.22
Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol (2009) 1.21
Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate (2010) 1.20
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Likelihood ratios for genome medicine. Genome Med (2010) 1.20
GWAS identifies a common breast cancer risk allele among BRCA1 carriers. Nat Genet (2010) 1.19
Prostate cancer incidence rates in Africa. Prostate Cancer (2011) 1.15
A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate (2012) 1.15
Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate (2012) 1.14
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate (2010) 1.12
Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate (2011) 1.10
Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med (2010) 1.09
Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res (2009) 1.09
Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.08
Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer (2010) 1.08
Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk. J Urol (2010) 1.08
Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol Biomarkers Prev (2010) 1.06
Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS One (2010) 1.05
Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis. Sci Signal (2013) 1.03
The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res (2011) 1.03
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin Cancer Res (2011) 1.01
Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men. Prostate (2013) 1.00
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. BJU Int (2013) 0.98
Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013) 0.97
Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. Prostate (2013) 0.96
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet (2015) 0.96
Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate (2010) 0.95
Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.95
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet (2013) 0.93
The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res (2013) 0.92
Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. Cancer Epidemiol Biomarkers Prev (2010) 0.91
Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis (2009) 0.91
The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget (2014) 0.90
Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. Cancer Epidemiol Biomarkers Prev (2014) 0.89
Comparison of statistical methods for estimating genetic admixture in a lung cancer study of African Americans and Latinos. Am J Epidemiol (2008) 0.89
Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study. Prostate (2010) 0.89
Association of a sequence variant in DAB2IP with coronary heart disease. Eur Heart J (2011) 0.89
The genomic landscape of prostate cancer. Int J Mol Sci (2013) 0.88
Joint analysis of tightly linked SNPs in screening step of genome-wide association studies leads to increased power. Eur J Hum Genet (2009) 0.88
CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med (2015) 0.87
Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. Oncotarget (2014) 0.86
A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). Int J Mol Epidemiol Genet (2010) 0.86
Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis (2012) 0.85
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet (2015) 0.85
Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate (2011) 0.85
Identification of new genetic risk factors for prostate cancer. Asian J Androl (2008) 0.85
A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genet Epidemiol (2012) 0.84
A common genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of lung cancer in Chinese males. PLoS One (2011) 0.84
Genome-wide two-locus epistasis scans in prostate cancer using two European populations. Hum Genet (2012) 0.84
A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. Cancer Epidemiol Biomarkers Prev (2011) 0.84
Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer. Diagn Pathol (2014) 0.83
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene (2016) 0.83
Replication of GWAS "Hits" by Race for Breast and Prostate Cancers in European Americans and African Americans. Front Genet (2011) 0.83
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. Biomed Res Int (2014) 0.83
Dab2IP GTPase activating protein regulates dendrite development and synapse number in cerebellum. PLoS One (2013) 0.83
Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. J Natl Cancer Inst (2007) 0.82
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2008) 7.14
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med (2010) 6.19
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Prostate cancer. N Engl J Med (2003) 5.91
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (2012) 5.82
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr (2009) 5.79
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med (2014) 5.05
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol (2011) 4.74
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47